Last reviewed · How we verify
lung parenchyma sampling
At a glance
| Generic name | lung parenchyma sampling |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Collagen Fingerprinting for Stratification of PH Patients
- Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy (NA)
- HOXB7 and Linked Tissue and Blood Biomarkers in the Lungs of Patients With Pulmonary Fibrosis
- In-depth Immunological Investigation of COVID-19.
- Clinical, Radiological, Tissue and Biological Phenotyping for the Analysis of the Transition From Physiology to Pathology in Pulmonary Diseases With Pulmonary Hypertension
- Inflammatory Profiling in Chronic Lung Disease
- Fibrosing ILD Biomarkers That Rule Acceleration
- Prognostic Value of Lung Cancer MicroAnatomy in 3D
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lung parenchyma sampling CI brief — competitive landscape report
- lung parenchyma sampling updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI